JP2007533742A5 - 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 - Google Patents
癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 Download PDFInfo
- Publication number
- JP2007533742A5 JP2007533742A5 JP2007509532A JP2007509532A JP2007533742A5 JP 2007533742 A5 JP2007533742 A5 JP 2007533742A5 JP 2007509532 A JP2007509532 A JP 2007509532A JP 2007509532 A JP2007509532 A JP 2007509532A JP 2007533742 A5 JP2007533742 A5 JP 2007533742A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- nucleobases
- antisense oligonucleotide
- gemcitabine hydrochloride
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000272 Oligonucleotide Polymers 0.000 title claims 9
- 201000011510 cancer Diseases 0.000 title claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 102000000763 Survivin Human genes 0.000 title 1
- 108010002687 Survivin Proteins 0.000 title 1
- 229960005277 gemcitabine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims 7
- 229960005144 Gemcitabine hydrochloride Drugs 0.000 claims 6
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 229940102223 Injectable Solution Drugs 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (11)
- 感受性腫瘍の治療のための併用療法における使用のための医薬の製造における、配列番号１に示されるヌクレオチド配列からなるアンチセンスオリゴヌクレオチド（ここに、ヌクレオシド間結合はすべてホスホロチオエート結合であり、５’末端における４の核酸塩基はそれぞれ２’−Ｏ−メトキシエチル糖を含み、３’末端における４の核酸塩基はそれぞれ２’−Ｏ−メトキシエチル糖を含み、中央の１０の核酸塩基は２’−デオキシヌクレオチドであり、シトシン残基はすべて５−メチルシトシンであり、該アンチセンスオリゴヌクレオチドはナトリウム塩の形態である）の使用であって、該医薬がゲムシタビン塩酸塩と組み合わせて投与される、使用。
- アンチセンスオリゴヌクレオチドがゲムシタビン塩酸塩の投与と同時に任意の順序にて投与される、請求項１記載の使用。
- アンチセンスオリゴヌクレオチドおよびゲムシタビン塩酸塩が治療有効期間内に任意の順序にて分別投与される、請求項１記載の使用。
- 併用療法が非経口経路を介する、請求項１から３のいずれか記載の使用。
- 非経口経路が静脈内投与である、請求項４記載の使用。
- 静脈内投与が緩慢注入である、請求項５記載の使用。
- アンチセンスオリゴヌクレオチドおよびゲムシタビン塩酸塩がそれぞれ滅菌注射用溶液の形態である、請求項１から６のいずれか記載の使用。
- 感受性腫瘍が膵臓癌、肺癌、乳癌、卵巣癌、膀胱癌、肝細胞癌、結腸直腸癌およびリンパ腫からなる群から選択される癌である、請求項１から７のいずれか記載の使用。
- 感受性腫瘍が肝細胞癌である、請求項８記載の使用。
- 配列番号１に示されるヌクレオチド配列からなるアンチセンスオリゴヌクレオチド（ここに、ヌクレオシド間結合はすべてホスホロチオエート結合であり、５’末端における４の核酸塩基はそれぞれ２’−Ｏ−メトキシエチル糖を含み、３’末端における４の核酸塩基はそれぞれ２’−Ｏ−メトキシエチル糖を含み、中央の１０の核酸塩基は２’−デオキシヌクレオチドであり、シトシン残基はすべて５−メチルシトシンであり、該アンチセンスオリゴヌクレオチドはナトリウム塩の形態である）と感受性腫瘍の治療における使用のための併用製剤としてのゲムシタビン塩酸塩を含む、製品。
- アンチセンスオリゴヌクレオチドおよびゲムシタビン塩酸塩がそれぞれ滅菌注射用溶液の形態である、請求項１０記載の製品。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56454004P | 2004-04-22 | 2004-04-22 | |
| PCT/US2005/012968 WO2005107771A2 (en) | 2004-04-22 | 2005-04-15 | Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007533742A JP2007533742A (ja) | 2007-11-22 |
| JP2007533742A5 true JP2007533742A5 (ja) | 2008-05-29 |
Family
ID=35094133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007509532A Pending JP2007533742A (ja) | 2004-04-22 | 2005-04-15 | 癌治療のための薬剤併用療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20070244065A1 (ja) |
| EP (3) | EP1763356B1 (ja) |
| JP (1) | JP2007533742A (ja) |
| CN (2) | CN101683355A (ja) |
| AT (2) | ATE401088T1 (ja) |
| AU (1) | AU2005240020B2 (ja) |
| BR (1) | BRPI0509927A (ja) |
| CA (1) | CA2562750A1 (ja) |
| CY (2) | CY1110440T1 (ja) |
| DE (1) | DE602005008241D1 (ja) |
| DK (2) | DK1763356T3 (ja) |
| ES (2) | ES2308488T3 (ja) |
| MX (1) | MXPA06012132A (ja) |
| PL (2) | PL1763356T3 (ja) |
| PT (2) | PT1913947E (ja) |
| SI (2) | SI1763356T1 (ja) |
| WO (1) | WO2005107771A2 (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2310006A4 (en) | 2008-07-03 | 2012-04-25 | Mayo Foundation | TREATMENT OF CANCER |
| FR2955112B1 (fr) | 2010-01-14 | 2012-01-20 | Isp Investments Inc | Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant |
| WO2012058462A2 (en) * | 2010-10-29 | 2012-05-03 | Isis Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| ES2792062T3 (es) | 2011-05-09 | 2020-11-06 | Mayo Found Medical Education & Res | Tratamientos contra el cáncer |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP3154595A4 (en) | 2014-06-16 | 2018-01-24 | Mayo Foundation for Medical Education and Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | INTERFERON CANCER TREATMENT METHODS |
| AU2017217881B2 (en) | 2016-02-12 | 2022-11-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| WO2017165439A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| KR20190053203A (ko) | 2016-09-01 | 2019-05-17 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | Ｔ－세포 암을 표적화하는 방법 및 조성물 |
| EP3506942B1 (en) | 2016-09-01 | 2022-11-16 | Mayo Foundation for Medical Education and Research | Carrier-pd-l1 binding agent compositions for treating cancers |
| US11311631B2 (en) | 2016-09-06 | 2022-04-26 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| CA3035655A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Methods of treating pd-l1 expressing cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE92499T1 (de) * | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| US6077709A (en) * | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
| US6838283B2 (en) * | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| EP1592793B2 (en) * | 2003-02-10 | 2014-05-07 | Santaris Pharma A/S | Oligomeric compounds for the modulation of survivin expression |
-
2005
- 2005-04-15 US US11/587,219 patent/US20070244065A1/en not_active Abandoned
- 2005-04-15 CN CN200910163328A patent/CN101683355A/zh active Pending
- 2005-04-15 CN CNA2005800118267A patent/CN1950094A/zh active Pending
- 2005-04-15 MX MXPA06012132A patent/MXPA06012132A/es active IP Right Grant
- 2005-04-15 AT AT05738307T patent/ATE401088T1/de active
- 2005-04-15 EP EP05738307A patent/EP1763356B1/en not_active Not-in-force
- 2005-04-15 DK DK05738307T patent/DK1763356T3/da active
- 2005-04-15 PL PL05738307T patent/PL1763356T3/pl unknown
- 2005-04-15 DE DE602005008241T patent/DE602005008241D1/de active Active
- 2005-04-15 AU AU2005240020A patent/AU2005240020B2/en not_active Ceased
- 2005-04-15 BR BRPI0509927-7A patent/BRPI0509927A/pt not_active IP Right Cessation
- 2005-04-15 PT PT07119706T patent/PT1913947E/pt unknown
- 2005-04-15 DK DK07119706.5T patent/DK1913947T3/da active
- 2005-04-15 WO PCT/US2005/012968 patent/WO2005107771A2/en active Application Filing
- 2005-04-15 EP EP09168514A patent/EP2145626A1/en not_active Withdrawn
- 2005-04-15 PT PT05738307T patent/PT1763356E/pt unknown
- 2005-04-15 PL PL07119706T patent/PL1913947T3/pl unknown
- 2005-04-15 JP JP2007509532A patent/JP2007533742A/ja active Pending
- 2005-04-15 SI SI200530382T patent/SI1763356T1/sl unknown
- 2005-04-15 CA CA002562750A patent/CA2562750A1/en not_active Abandoned
- 2005-04-15 ES ES05738307T patent/ES2308488T3/es active Active
- 2005-04-15 SI SI200531449T patent/SI1913947T1/sl unknown
- 2005-04-15 ES ES07119706T patent/ES2376484T3/es active Active
- 2005-04-15 AT AT07119706T patent/ATE538800T1/de active
- 2005-04-15 EP EP07119706A patent/EP1913947B1/en not_active Not-in-force
-
2008
- 2008-09-24 CY CY20081101036T patent/CY1110440T1/el unknown
-
2009
- 2009-03-13 US US12/403,561 patent/US20090247611A1/en not_active Abandoned
-
2011
- 2011-09-28 US US13/246,890 patent/US20120022140A1/en not_active Abandoned
-
2012
- 2012-02-24 CY CY20121100197T patent/CY1112397T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533742A5 (ja) | 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 | |
| JP2007505627A5 (ja) | ||
| ES2576677T3 (es) | Análogos de ARN interfirientes cortos | |
| KR102183273B1 (ko) | 펩타이드 올리고뉴클레오타이드 접합체 | |
| JP2019108405A (ja) | オリゴマーおよびオリゴマー・コンジュゲート | |
| ES2718082T3 (es) | Tratamiento contra el cáncer | |
| JP2018126141A5 (ja) | ||
| ES2706198T3 (es) | Conjugados de ácido borónico de análogos de oligonucleótidos | |
| JP2018528781A5 (ja) | ||
| JP2016522817A5 (ja) | ||
| JP2012050438A5 (ja) | ||
| JP2011501962A5 (ja) | ||
| JP2017505623A5 (ja) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| EP2448952B1 (en) | Novel guanosine-rich modified oligonucleotides and antiproliferative activity thereof | |
| JP2010539950A5 (ja) | ||
| EP3066105A1 (en) | Polynucleotide constructs having disulfide groups | |
| JP2010515707A5 (ja) | ||
| KR20060015505A (ko) | 올리고뉴클레오타이드 전구약물 | |
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| BR112020020220A2 (pt) | Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b | |
| KR102627418B1 (ko) | 변형된 올리고뉴클레오티드 및 사용 방법 | |
| TWI762732B (zh) | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 | |
| WO2011084694A1 (en) | Stabilized stat3 decoy oligonucleotides and uses therefor | |
| CN105779458B (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 |